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Background: Epidemiologic data indicates that Asian diets, which are high in soy protein, reduce a women’s risk of
developing breast cancer. However, it has been difficult to dissociate the benefits of soy from other variables
including environmental and lifestyle factors. Since prospective studies in humans would take decades to complete,
rodent models provide a valuable research alternative.
Methods: In this study, MTB-IGFIR transgenic mice, which develop mammary tumors resulting from overexpression
of the type I insulin-like growth factor receptor (IGF-IR), were utilized. MTB-IGFIR mice were fed a soy-based or
casein-based diet throughout all stages of development to reflect soy exposure in Asian cultures. Mammary tumors
were initiated at 2 different developmental stages by commencing IGF-IR transgene expression either during
puberty or in adult mice.
Results: MTB-IGFIR mice fed a soy-based diet displayed increased tumor incidence and accelerated tumor onset
compared to MTB-IGFIR mice fed a casein diet. Two markers of estrogen receptor signaling, Pgr and Areg, were
elevated in mammary tissue from mice fed the soy diet compared to mice fed the casein diet suggesting that high
levels of soy may promote mammary tumor development through acting as an estrogen receptor agonist.
Mammary tumors from mice fed a soy diet more frequently expressed metaplastic markers such as cytokeratins 5
and 14 as well as p63 and displayed reduced lung metastases compared to mammary tumors from mice fed a
casein diet.
Conclusions: Diets consisting of very high levels of soy protein promote mammary tumor development and
decrease tumor latency possibly through activating estrogen receptor signaling. Additional studies are required to
determine whether a more moderate amount of dietary soy can inhibit oncogene-induced mammary
tumorigenesis.
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Breast cancer rates vary depending on geographical loca-
tion with the incidence of breast cancer being relatively
high in North America and Western Europe compared
to Asian countries such as Japan and China [1]. One fac-
tor implicated in contributing to the lower breast cancer
rates observed in Asian countries is the high consump-
tion of soy products. In countries such as China, soy* Correspondence: rmoorehe@uoguelph.ca
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unless otherwise stated.consumption ranges from 27-141 g of soy per day while
individuals born in the United States, Canada and Western
Europe typically consume less than 4 g of soy per day [2].
Soy has been shown to contain several putative chemo-
preventative agents including isoflavones [3]. Isoflavones
are plant derived phytoestrogens and the main isoflavones
found in soy are genistein, daidzein and glycitein [4]. Iso-
flavones bind weakly to estrogen receptors (ERα and ERβ)
and appear to preferentially bind to ERβ [5-8]. Based on
their affinity for ERs it has been proposed that soy isofla-
vones can reduce breast cancer risk by interfering with thel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ER signaling.
The protective effects of soy have been demonstrated
in case–control and cohort studies in Asian populations
in that soy consumption was inversely associated with
breast cancer risk [9-13]. Reductions in risk of 29% have
been reported when women consuming high levels of soy
isoflavones (>20 mg/day) are compared to those con-
suming low levels of soy isoflavones (<5 mg/day) [14].
However, a subset of studies failed to show a benefit in
soy consumption with respect to breast cancer. Three
case–control, six cohort and six prospective studies have
failed to demonstrate any significant association between
soy consumption and breast cancer risk (reviewed in [4]).
One of these studies actually showed that soy consump-
tion was associated with increased breast cancer risk [15].
A very recent study by Shike et al. [16] demonstrated in a
randomized-placebo controlled study that soy supplemen-
tation for 7–30 days in women with early stage breast can-
cer increased the expression of a number of cell cycle
related genes compared to women receiving a placebo.
Therefore, under certain conditions soy consumption may
provide little or no benefit and in some scenarios, have
detrimental effects.
Since it is difficult to design studies to assess the
causal association between dietary soy and mammary
tumor risk as well as the mechanism through which soy
modifies mammary tumorigenesis in humans, animal
models have also been employed. Most of the animal
studies performed to date have explored the impact of
soy or specific isoflavones on chemically induced mam-
mary tumors in rodents. Using these models, it has been
shown that soy or specific isoflavones inhibit mammary
tumor development induced by chemicals such as 7,12-
dimethylbenz(a)anthracene (DMBA) and nitrosomethy-
lurea (NMU) [17-22]. It should be noted that a small
number of studies have failed to demonstrate a protect-
ive effect of soy isoflavones and in some situations diet-
ary soy consumption enhanced chemically-induced
mammary tumorigenesis [23-25].
More recently, transgenic mice have been used to de-
termine whether dietary soy protects against mammary
tumor development. MMTV-Wnt1 mice fed a soy diet
after weaning exhibited reduced mammary tumor inci-
dence but significantly shorter tumor latency compared
to mice fed a casein diet [26]. In a study using MMTV-
erbB2 transgenic mice, the animals were manipulated to
have low, moderate or high levels of estrogen and then
placed on a soy or control diet 2 weeks after hormone
manipulation. This study found that soy significantly in-
duced mammary tumor development in the low estro-
gen group, inhibited mammary tumor development in
the high estrogen group and had no effect on the mod-
erate estrogen group [27]. Another study using MMTV-erbB2 transgenics showed that initiating a soy diet at 2
months of age had no effect on mammary tumor devel-
opment compared to a soy-free diet [28].
The animal studies performed to date do suffer from
some limitations. First, diets high in soy or isoflavones
are often initiated during postnatal development while
Asian populations presumably consume high levels of
soy throughout their lives and thus Asian women are ex-
posed to soy isoflavones during embryonic and postnatal
development. Data from human studies suggest that al-
though soy intake at any age decreases breast cancer
risk, the greatest decrease in risk was associated with
high dietary soy intake during childhood [12,29-31]. A
second limitation is the timing of mammary tumor
transformation. DMAB or NMU are often administered
as a single, high dose during pubertal development, an
induction scenario that is unlikely to recapitulate breast
cancer initiating events in humans. The mouse mam-
mary tumor virus (MMTV) promoter which is typically
used to drive the expression of transgenes in mouse
mammary tissue is active at all stages of development
and thus the tumor inducing oncogene is expressed dur-
ing the later stages of embryonic development and all
stages of postnatal development. This pattern of onco-
gene expression may reflect inherited gene alterations/
mutations, however, only 20-25% of breast cancers are
thought to be familial [32].
Our study was designed to minimize the limitations of
other animal models. To accomplish this, soy or casein
diets were administered to female mice prior to mating
and the females were maintained on the same soy or ca-
sein diet during lactation. Upon weaning the offspring
were also maintained on the soy or casein diet to ensure
female MTB-IGFIR transgenic mice were exposed to
the soy or casein diet throughout all stages of develop-
ment. Since it remains unclear when breast cancer initi-
ation occurs, the IGF-IR transgene was induced at two
different developmental stages, during puberty and in
young, post-pubertal mice. Induction of the IGF-IR
transgene at these two stages would simulate a spontan-
eous genetic alteration acquired in pubertal or young
adult women.
Using this experimental design, mice fed a soy-based
diet had a significant increase in tumor incidence and
shorter tumor latency than mice fed a casein-based diet.
Mammary tumors from mice fed a soy diet more fre-
quently expressed markers associated with metaplastic
breast cancer including cytokeratin 5, cytokeratin 14, p63
and the presence of osseous matrix. The soy diet appeared
to have a protective effect against tumor progression as
lung metastases were more frequent in casein-fed mice.
Although it is unclear how dietary soy promotes mam-
mary tumorigenesis, two estrogen regulated genes, Pgr
and Areg were expressed at higher levels in mammary
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soy on estrogen receptor signaling.
Methods
Ethics
Animals were housed and cared for following guidelines
established by the Central Animal Facility at the University
of Guelph and the guidelines established by the Canadian
Council of Animal Care. This study was approved by the
Animal Care Committee at the University of Guelph (AUP#
1695) and all efforts were made to minimize suffering.
Mice
MTB-IGFIR transgenic mice were generated in our lab
and have been previously described [16]. At the time of
mating, mice were placed on a diet where the sole
source of protein was from casein or isolated soy protein
and mice were maintained on this diet throughout preg-
nancy and lactation. Following weaning (21 days of age)
the mice were maintained on either the casein or soy di-
ets. At either 45 days of age or 100 days of age female
MTB-IGFIR mice were switched to either the casein
diet + 100 mg of doxycycline per kilogram of food or the
soy diet + 100 mg of doxycycline per kilogram of food.
Mice were maintained on the doxycycline supplemented
diet until the end of the study. All diets were obtained
from Harlan Laboratories (Madison, WI) and the de-
tailed composition of each diet is provided as supple-
mentary data (Additional file 1: Table S1). The isolated
soy protein used by Harlan typically contains approxi-
mately 463 ppm, 95 ppm, 933 ppm, 101 ppm, 57 ppm
and 9 ppm of daidzin, daidzein, genistin, genistein, gly-
cetin and glycetein, respectively with a total isoflavone
content of approximately 1660 ppm, all aglycone.
Tumor onset and growth rate
Mammary tumor onset was determined by palpation.
Once a mammary tumor was identified it was measure
approximately three times per week using digital cali-
pers. Tumor volume was estimated using the formula:
volume = length x width2/2. Tumor specific growth
rate (SGR) was estimated using the formula: SGR = ln
(V2/V1)/(t2-t1) [31].
Histology and immunohistochemistry
Histology and immunohistochemistry were performed as
previously described [33]. The antibody against IGF-IR
was obtained from R&D Systems (Minneapolis, MN),
while antibodies against cytokeratin 5, cytokeratin 8,
cytokeratin 14, and p63 were all obtained from Abcam
(Toronto, ON, Canada). The p63 antibody was used at a
dilution of 1:750 while the antibodies for IGF-IR cyto-
keratin 5, cytokeratin 8, and cytokeratin 14 were used at
a dilution of 1:100.Goldner’s trichrome staining
Tissue sections were de-waxed in xylene and then re-
hydrated in decreasing concentrations of alcohol ending
with water. The sections were then stained for 20 minutes
with Weigert’s iron hematoxylin and rinsed in water for 1
minute. Sections were then differentiated by incubating in
1% hydrochloric acid in 70% ethanol for 5 seconds and
then rinsed in water. Next, sections were stained for 5 mi-
nutes in solution A (0.075% Ponceau 2R, 0.025% acid
fuchsin, 0.01% azophloxine and 0.2% acetic acid in dis-
tilled water), 3 minutes in solution B (2% orange G and
4% phosphomolybdic acid in distilled water) and 5 mi-
nutes in solution C (0.2% light green and 0.2% acetic acid
in distilled water). Between solution A and B as well as be-
tween solution B and C, the sections were rinsed with 1%
acetic acid. Sections were then incubated in 1% acetic acid
for 5 minutes, rinsed in 100% alcohol, and mounted. All
steps were performed at room temperature.
Western blotting
Western blotting was performed as previously described
[34]. Primary antibodies for Akt, phosphorylated Akt
(Ser473), Erk1/2, phosphorylated Erk1/2 (Thr202/Tyr204),
STAT3 and phosphorylated STAT3 (Tyr705) were pur-
chased from Cell Signaling Technologies (Beverly, MA)
and were used at a 1:1,000 dilution. The primary antibody
for IGF-IR was obtained from R&D Systems (Minneapolis,
MN) and was used at a 1:2,000 dilution. HRP-conjugated
secondary antibodies were obtained from Cell Signaling
Technologies (Beverly, MA) and were used at a 1:2,000 di-
lution. Images were captured on ChemiDoc XRS+ imaging
system (Bio-Rad Laboratories, Mississauga, ON Canada)
and band intensities were determined using Image Lab soft-
ware (Bio-Rad Laboratories, Mississauga, ON Canada).
RNA extraction and real-time PCR
RNA was extracted from mammary tissue using the mir-
Vana miRNA isolation kit (Life Technologies, Burlington,
ON, Canada) following the manufacturer’s instructions.
RNA was reverse transcribed as previously described [35].
Quantitative RT-PCR was performed using Platinum
SYBR Green qPCR SuperMix (Life Technologies, Burling-
ton, ON, Canada) and Cq values were determined using
the PrimePCR program on a CFX96 real-time PCR ma-
chine (Bio-Rad Laboratories, Mississauga, ON, Canada) as
determined by the CFX Manager software v3.1 (Bio-Rad
Laboratories, Mississauga, ON, Canada). Primers for Esr1
and Pgr were obtained from Origene (Rockville, MD)
while primers for Areg, Fgf10, Fgfr1, Fgfr2, Tgfα, Hprt and
Ywhaz were obtained from Bio-Rad Laboratories
(Mississauga, ON Canada). Primer efficiencies were
Esr1 – 91.3%, Pgr – 92.5%, Areg – 101.1%, Fgf10 – 109.3%,
Fgfr1 – 103.2%, Fgfr2 – 98.6%, Hprt – 105.0%, Tgfα- 92.1%
and Ywhaz – 110.0%. Relative gene expression was
Watson et al. BMC Cancer  (2015) 15:37 Page 4 of 13calculated using CFX manager software version 3.1
(Bio-Rad Laboratories, Mississauga, ON Canada) and
Hprt and Ywhaz were used for normalization. Hprt and
Ywhaz had previously been identified as the as appro-
priate housekeeping genes from a reference gene panel
of 14 genes which also included Tbp, Actb, Gusb,
Gapdh, B2m, Rps18, G6pdx, Hmbs, Nono, Ppia, Tfrc
and Rpl13a (Bio-Rad Laboratories, Mississauga, ON
Canada) using geNorm [36].
Statistics
Kaplan-Meier curves were generated in SPSS version 20
(IBM, Armonk, NY) and used to compare the tumor on-
set between the soy and casein diet groups. A Log Rank
(Mantel-Cox) test was used to determine whether the
Kaplan-Meier curves were significantly different. An
ANOVA followed by a Tukey’s post-hoc test was used
to compare tumor onset following administration of dif-
ferent concentrations of doxycycline. A Fisher’s Exact
test was used to compare the number of mice that de-
veloped mammary tumors and the number of tumor
bearing mice that developed lung metastases between
the two diets. A Student’s T-test was used when com-
paring gene expression between the two diets. In all
cases, p < 0.05 was considered statistically significant.
Results
Titration of IGF-IR transgene expression modulates
mammary tumor onset in MTB-IGFIR mice
Our original study with the MTB-IGFIR transgenic mice
used 2g of doxycycline (DOXC) per litre of water or per
kilogram of rodent chow to induce high levels of the
IGF-IR transgene in mammary epithelial cells [34,37].
This level of IGF-IR expression induced mammary tu-
mors in the MTB-IGFIR transgenic mice within approxi-
mately 50 days [34]. Since mammary tumor onset was
so rapid at this level of IGF-IR expression, it may be dif-
ficult for dietary alterations to influence mammary tumori-
genesis. To establish a more reasonable rate of tumorTable 1 Mammary tumor development and metastatic spread






13 13 108 ± 9
Casein
(PND45)
9 7 179 ± 231*
Soy
(PND100)
16 15 205 ± 201
Casein
(PND100)
12 5** 190 ± 301
1only mice that developed tumors were included.
*p < 0.05 compared to Soy PND45 (Student’s T-test).
**p < 0.05 compared to the number of tumors in Soy PND100 (Fisher’s Exact Test).onset, MTB-IGFIR mice were fed 1 g/kg, 500 mg/kg,
250 mg/kg and 100 mg/kg of DOXC in the animals’ food.
It was found that tumor onset was delayed only in the
MTB-IGFIR mice fed 100 mg/kg DOXC and using this
concentration of DOXC, mammary tumors were induced
within average onset of 157 ± 26.5 days (Additional file 2:
Figure S1A). The delay in mammary tumor onset was
likely due to the significant reduction in IGF-IR protein
induced by 100 mg/kg DOXC compared to 2 g/kg DOXC
(Additional file 2: Figure S1B,C). 100 mg/kg DOXC was
used to induce mammary tumors in this study.
Tumor onset, incidence, multiplicity and growth rate
To evaluate the effect of dietary soy on oncogene-
induced mammary tumorigenesis, mice were main-
tained on soy-based or casein-based diets throughout
embryonic and postnatal development. To achieve this,
female mice were exposed to either the soy or casein
diet at the time of mating and remained on this diet
until the mice were weaned. Once the mice were weaned,
they remained on the soy- or casein-based diet until they
were euthanized.
The IGF-IR transgene was induced at two different
time points, postnatal day 45 (PND45) and PND100.
These time points were selected to initiate mammary
tumor development in pubertal mice (PND45) or young
adult mice (PND100) [38,39]. Mice were monitored for
a maximum of one year after the induction of the IGF-IR
transgene. Mice that did not develop tumors by this point
were euthanized and mammary glands collected.
When the IGF-IR transgene was induced at PND45, it
was observed that 13/13 of the mice fed the soy diet de-
veloped mammary tumors within the first year after
IGF-IR transgene induction while only 7/9 mice fed the
casein diet developed mammary tumors within this time
frame (Table 1). The two casein mice that did not de-
velop mammary tumors had normal mammary glands
based on histological analysis and expressed high levels






# of mice with
lung metastases
2.1 ± 0.31 3.1 ± 0.3 5
1.9 ± 0.41 3.2 ± 0.6 3
1.9 ± 0.31 3.2 ± 0.4 4
1.6 ± 0.41 3.7 ± 0.3 4
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expressed at high levels in these mammary glands.
Kaplan-Meier curves for tumor onset following IGF-IR
induction at PND45 are presented in Figure 1A. Based
on these curves it was determined that mice fed the soyFigure 1 Kaplan-Meier curves of tumor-free mice fed either a soy (sol
induced at (A) PND45 or (B) PND100. Tumor development was significan
induction times.diet had significantly faster tumor onset than mice fed
the casein diet. Average tumor onset for the mice receiving
the soy diet was 108 ± 9 days after IGF-IR transgene induc-
tion while average tumor onset for the mice receiving the
casein diet was 179 ± 23 days.id line) or casein (dashed line) diet and had the IGF-IR transgene
tly faster in the soy-fed mice compared to the casein-fed mice at both
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it was observed that 15/16 of the mice fed the soy diet
developed mammary tumors within the first year after
IGF-IR transgene induction while only 5/12 mice fed the
casein diet developed mammary tumors within this time
frame (Table 1, Figure 1B). Mammary glands from mice
that did not develop mammary tumors, appeared pheno-
typically normal and expressed high levels of the IGF-IR
transgene (data not shown). Kaplan-Meier curves revealed
that tumor onset was significantly accelerated in the soy-
fed mice compared to the casein-fed mice (Figure 1B).
There was no significant difference in the average
number of mammary tumors that developed in each
mouse on the two different diets at either time point
(Table 1). In addition, tumor specific growth rate (SGR)
was not significantly different between the two diets at
either time point (Table 1).Figure 2 Representative H&E stained section (A), IGF-IR
immunohistochemistry (B) and cytokeratin 8 immunohistochemistry
(C) of the mammary tumors that developed in the soy-fed and
casein-fed mice following IGF-IR transgene induction. Scale
bars, 100 μM.Tumor histology
Histological evaluation of the mammary tumors revealed
that tumor cells from both the casein- and soy-fed mice
typically possessed a shape consistent with luminal
tumor cells (Figure 2A). IGF-IR immunohistochemistry
indicated that most of the tumor cells in both diets
expressed moderate to high levels of IGF-IR (Figure 2B).
Regions of necrosis were frequently observed in tumors
from both diets (Figure 2A). Tumor cells with a luminal
morphology typically stained positive for cytokeratin 8
(Figure 2C).
Another frequent characteristic of these tumors was
pockets of cells that stained positive for basal cytokera-
tins such as cytokeratin 5 (Figure 3A,B) or cytokeratin
14 (Figure 3C,D). Cells staining positive for basal cytoke-
ratins were also frequently positive for p63 (Figure 3E,F).
Additional file 4: Figure S3 shows the expression of cyto-
keratin 5 (CK5), cytokeratin 14 (CK14) or p63 in the dif-
ferent tumors.
Interestingly, a subset of tumors contained a white/
grey substance that was visible following H&E staining
(Figure 4A,B). This material was only observed in tu-
mors from soy-fed mice when the IGF-IR transgene was
induced at 100 days of age (5/15 mice) and was not
found in any other tumors. Goldner’s Trichrome staining
suggested that these deposits may be a type of matrix
such as osteoid (Figure 4C,D).Lung metastasis
Lung metastases were identified using IGF-IR immuno-
histochemistry (Additional file 5: Figure S4A) since
mammary tumors that metastasize to the lung maintain
high levels of IGF-IR transgene. This approach also
allowed for the identification of small lung metastases
(Additional file 5: Figure S4B). All lobes of the lungsfrom each mouse were evaluated in one randomly chosen
tissue section.
It was observed that 5/13 (38%) of the soy-fed mice that
developed mammary tumors had at least one metastatic
lesion while 3/7 (43%) of the casein-fed mice that devel-
oped mammary tumors had at least one metastatic lesion
when the IGF-IR transgene was induced at PND45
Figure 3 Representative immunohistochemistry for cytokeratin 5 (A,B), cytokeratin 14 (C,D) and p63 (E,F) from a mammary tumor that
developed in a soy-fed mouse following IGF-IR induction at 100 days of age at 200x (A,C,E) or 600x (B,D,F) magnification. Scale bars in
A,C,E are 100 μM while scale bars in B,D,F are 33 μM.
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PND100, it was observed that 4/15 (27%) of the soy-fed
mice had at least one metastatic lesion while 4/5 (80%) of
the casein-fed mice had at least one metastatic lesion
(Table 1). The metastatic frequency of the casein-fed mice
was nearly statistically different from the soy-fed mice
when the IGF-IR transgene was induced at PND100 (p =
0.054). When the data are pooled, 7/12 (58%) casein-fed
and 9/28 (32%) soy-fed mice developed lung metastases
(p = 0.087).
When the lungs were examined from tumor bearing mice
individual lobes would typically contain 0–4 lung metasta-
ses and the total number of lung metastases in a tumor-
bearing mouse ranged from 1–8 metastases. However, one
mouse fed the casein diet and IGF-IR transgene induction
at PND45 developed multiple lung metastases throughouteach lobe (Additional file 6: Figure S5A,B). It remains un-
clear why this one mouse had such extensive metastatic
burden. Analysis of the primary mammary tumor revealed
that the tumor was composed of cells with luminal appear-
ance that maintained some glandular structure and had
considerable amounts of intervening stroma (Additional
file 6: Figure S5C). Only 1 other mouse had a mammary
tumor with similar morphologic features and this mouse
was fed the casein diet and had the IGF-IR transgene in-
duced at PND100 (data not shown). While this tumor me-
tastasized to the lung only 3 small lung metastases were
visible across all the lung lobes (data not shown).
There was no consistent difference with respect to the
total number of lung metastases or the size of the le-
sions between the two diets at either time point of
IGF-IR induction.
Figure 4 A representative H&E stained section (A,B) or Goldner’s stained section (C,D) of a mammary tumor from a soy-fed mice with
IGF-IR induction at 100 days of age. A white matrix-like material was observed in five tumors from soy-fed mice and this matrix stained
red/orange following Goldner’s staining suggesting the matrix may be osteoid. Scale bars for A,C are 100 μM while scale bars for B,D are 33 μM.
Figure 5 Western blot analysis for IGF-IR, Akt, phosphorylated
Akt (Ser473), Erk1/2, phosphorylated Erk1/2 (Thr202/Tyr204),
STAT3 and phosphorylated STAT3 (Tyr705) in mammary tumors
from mice fed soy or casein diets. β-actin served as a
loading control.
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Western blotting was performed on tumors taken from
four independent mice for each diet when the IGF-IR
was induced at PND45 or PND100. Tumors were eval-
uated for IGF-IR, Akt, Erk1/2 and STAT3 as well as
the phosphorylated forms of Akt, Erk1/2 and STAT3.
As shown in Figure 5 there were no obvious differences
in the levels of IGF-IR, Akt, Erk1/2 or STAT3 in the
mammary tumors derived from mice fed soy or casein
diets.
Gene expression in Soy and casein mammary glands
Phytoestrogens in soy are capable of activating estrogen
receptors albeit with a lower potency than endogenous
estrogens. To evaluate whether a diet where soy was the
sole source of protein could influence estrogen receptor
level or signalling, RNA was extracted from mammary
glands of 45 day old, MTB-IGFIR mice fed a soy or
casein diet throughout embryonic and postnatal devel-
opment that were not exposed to DOXC. As shown inTable 2, the soy diet did not significantly change the expres-
sion levels of estrogen receptor alpha (Esr1). Progesterone
receptor (Pgr) expression was approximately 2.2-fold higher
in the soy-fed mice compared to the casein-fed mice but
this difference was not statistically significant as there
Table 2 Gene expression in mammary glands from mice
fed soy or casein diets





(soy relative to casein)
Esr1 2.56 ± 0.37 3.64 ± 0.88 0.7
Pgr 0.24 ± 0.08 0.11 ± 0.04 2.2
Areg 1.43 ± 0.32 0.57 ± 0.18* 2.5
Tgfα 0.13 ± 0.03 0.12 ± 0.03 1.2
Fgf10 1.32 ± 0.09 2.10 ± 0.41 0.6
Fgfr1 3.65 ± 0.58 4.80 ± 0.92 0.8
Fgfr2 1.01 ± 0.07 0.79 ± 0.20 1.3
1normalized to Hprt and Ywhaz.
*p < 0.05, Student’s t-test.
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mammary samples.
The expression of additional regulators of mammary
epithelial proliferation were also investigated including
amphiregulin (Areg), fibroblast growth factor 10 (Fgf10),
FGF receptor 1 (Fgfr1), Fgfr2, and transforming growth
factor alpha (Tgfα). As shown in Table 2, high levels of
Fgf10 and Fgfr1, moderate levels of Fgfr2 and Areg and
only low levels of Tgfα were found in the mammary tis-
sue. The only gene that was significantly elevated in the
mammary glands of soy-fed mice was Areg and this gene
was expressed approximately 2.5-fold higher in mam-
mary glands from soy fed compared to mammary glands
from casein fed mice.
Discussion
The goal of this project was to determine whether a diet
where soy was the sole source of protein could protect
against the development of mammary tumors mediated
by the mammary-tumor inducing oncogene, IGF-IR. To
model soy exposure in Asian cultures, mice were ex-
posed to soy protein throughout embryonic develop-
ment and during nursing by feeding the mothers of the
offspring diets high in soy or diets lacking soy and the
mice were maintained on the high soy or soy-free diet
upon weaning. Since there is still considerable debate re-
garding the age when the initial events of mammary
tumorigenesis occur, mammary tumors were induced at
two time points; in pubertal mice and in young adult
mice.
In our study, animals fed the high soy diet displayed
increased mammary tumor incidence and shorter tumor
latency compared to mice fed a soy-free, casein-based
diet. This enhanced mammary tumor incidence and on-
set was observed when the IGF-IR transgene was in-
duced in mammary epithelial cells at 45 and 100 days of
age. This finding is surprising considering that studies in
humans suggest that a diet high in soy protein protects
against mammary tumor development. The main differencebetween our study and those carried out in humans is that
in our work 100% of the dietary protein came from soy
protein. Asian cultures consume ~20-141 g of soy per day
[2]. Using 55 kg as an estimate of the average weight for
an Asian women, the upper limit of soy consumption
would be approximately 2.6 g of soy/kg body weight/day.
Mice eat approximately 5 g/day and the diet provided to
our mice contained 0.2 g of soy protein/g of food. With an
average weight of 25 g, our mice were consumed approxi-
mately 40 g of soy/kg body weight/day. This soy consump-
tion is ~15-fold higher than the upper amount of soy
reported to be consumed by Asian women. Therefore, it is
possible that very high levels of soy used in our study
acted as a tumor promoter, whereas more moderate soy
intake may prevent mammary tumorigenesis.
A majority of the animal studies evaluating the chemo-
preventative effects of soy have been performed in rats
exposed to chemical carcinogens. These studies typically
do not initiate soy administration until the postnatal
period and thus it is difficult to compare our findings to
these studies. Two studies did however evaluate the im-
pact of dietary soy on mammary tumor development
when rats were exposed to soy during embryogenesis. In
a study by Hilaviki-Clarke et al., daily subcutaneous in-
jections of 20, 100 or 300 ug of genistein during days 15
and 20 of gestation, increased the incidence of mammary
cancer following DMBA administration to rats at 2
months of age [40]. Lamartiniere et al., fed rats diets
containing 0, 25 or 250 mg of genistein/kg of food be-
ginning two weeks before mating and the offspring were
maintained on the diet until weaning at which point the
female offspring were placed on a soy-free diet. DMBA
was administered at 50 days of age to initiate tumor de-
velopment. Using this design, both the 25 and 250 mg of
genistein inhibited mammary tumor multiplicity [41].
Lamartiniere et al. then altered the soy exposure such
that females were fed a diet containing 250 mg of genis-
tein/kg of food only during breeding and pregnancy and
females were switched to a soy-free diet at parturition.
Feeding soy only during breeding and pregnancy did not
significantly reduce the tumor multiplicity compared to
control mice [41] suggesting that soy exposure during
the embryonic phase had no effect on mammary tumor
development in this study.
Evaluation of normal mammary development also sug-
gests that soy isoflavones can result in changes in the
mammary gland that may promote tumor development.
In one study, administration of the soy metabolite,
equol, to rats during neonatal development led to preco-
cious mammary gland differentiation compared to pre-
pubertal treatment (days 21–35) [30]. In addition, rats
administered genistein during embryonic development
and lactation had abnormal mammary gland histology
including regions of hyperplasia and increased mammary
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end buds [42]. Finally, administration of increasing con-
centrations of genistein during embryonic and postnatal
development induced mammary gland hyperplasia in
both male and female rats at PND50 when genistein was
administered at 250 ppm or higher [43].
Studies administering soy diets to transgenic mice have
also shown conflicting results. A study by Chiesa et al.
[44] fed MMTV-neu transgenic mice a diet high in soy
protein and soy isoflavones during gestation and lactation.
At weaning, mice received a soy-free diet, a diet high in
soy protein and soy isoflavones or a diet high in soy pro-
tein but containing low levels of soy isoflavones. All mice
developed mammary tumors and the mice fed an
isoflavone-poor, soy protein concentrate had significantly
lower tumor weight at the time of sacrifice (5 months of
age). In a study by Luijten et al. [45] diets containing low,
moderate or high levels of soy isoflavones were adminis-
tered either during pregnancy and lactation or at 4 weeks
of age to MMTV-neu transgenic mice. In the perinatal ex-
posure group, the average number of tumors and total
tumor mass was significantly higher in the medium and
high soy diet groups. In the post-weaning study, soy had
no effect on tumor incidence, tumor multiplicity or total
tumor mass. Two studies that evaluated the impact of soy
administration to pubertal MMTV-neu transgenic mice
found that soy administration delayed mammary tumor
development [46,47]. Thus, the impact of dietary soy on
oncogene-induced mammary tumor development requires
further investigation to determine whether soy consump-
tion can prevent mammary tumor development and if so,
the optimal amount of soy that should be consumed and
the developmental window that soy consumption would
provide the greatest benefit.
The mechanism through which soy isoflavones regu-
late mammary tumorigenesis remains unclear but most
likely involves signaling through ERs. Estrogen is one of
the main regulators of mammary epithelial proliferation
[48-54] and soy isoflavones can bind to the estrogen re-
ceptor and either promote or inhibit estrogen receptor
signaling depending on the level of endogenous estrogen
[27,55]. Our data suggests that administration of a diet
high in soy throughout embryonic and postnatal devel-
opment can induce ER signaling in the mammary glands
of pubertal mice. Genes with the greatest increase in ex-
pression in mammary tissue of soy-fed mice compared
to the casein-fed mice were Pgr and Areg, both of which
are regulated by ER signalling (Dragon Estrogen Respon-
sive Genes Database [ERGDB] found at datam.i2r.a-star.
edu.sg/ergdbV2/). Areg is a member of the epidermal
growth factor family (EGFR) and is expressed at higher
levels than any other EGF family member in the pubertal
mammary gland [56]. The AREG protein mediates mam-
mary epithelial proliferation in both ducts and terminalend buds [57,58]. Our data are the first report that diet-
ary soy can influence Areg expression in mammary
glands and thus provides a potential mechanism through
which dietary soy can influence mammary epithelial pro-
liferation and potentially transformation.
A number of other genes implicated in mammary gland
development were evaluated in the mammary tissue of
mice fed soy and casein diets including Fgf10, Fgfr1, Fgfr2,
and Tgfα [59-61]. None of these genes were expressed at
significantly different levels in the mammary glands of
soy-fed mice compared to those of casein-fed mice sug-
gesting that these genes are not contributing to soy’s influ-
ence on mammary tumor development.
One potential protective effect of soy observed in our
study was a 3-fold reduction in the percentage of soy-fed
mice with metastatic lesions compared to the casein-fed
mice when the IGF-IR transgene was induced at 100
days of age. The difference in metastatic incidence how-
ever, was not significant due to the small number of
casein-fed mice that developed mammary tumors. A de-
crease in the percentage of soy-fed mice with lung mes-
tatases is consistent with most of the studies in the
literature that demonstrate that soy or isoflavones inhibit
mammary tumor migration and metastasis [62-66], how-
ever, at least one study found that isoflavones increased
metastasis of MDA-MB-435 cells in immunocomprom-
ised mice [67]. It has been shown in breast, prostate and
other cancers that soy isoflavones can inhibit cell de-
tachment, invasion and the expression of proteases such
as MMP-2 and MMP-9 [65,66,68]. The inhibitory effects
of soy on tumor progression may explain the inverse re-
lationship between soy consumption and breast cancer
mortality and recurrence [69].
The consumption of high levels of dietary soy also ap-
pears to impact mammary tumor morphology. Mammary
tumors from soy-fed mice more frequently contained a
mixture of luminal and basal/mesenchymal cells than
mammary tumors from casein fed mice. Tumors express-
ing luminal and basal cell types have been described in
humans and classified as metaplastic breast cancers. This
is a rare subtype of breast cancer representing 0.2-5% of
all breast cancers and was the focus of a recent commen-
tary in Nature Reviews Cancer [70]. Metaplastic breast
cancers are typically ER-, PR- and HER2- and thus share
features with triple negative breast cancer [70-73]. These
tumors also typically express cytokeratins 5 and 14 and
p63 [71,73,74], which is the staining pattern more fre-
quently observed in mammary tumors from soy-fed mice
than casein-fed mice in our study. Since this tumor sub-
type is rare little is known about it other than the fact that
patients with metaplastic breast cancer typically have poor
prognosis and do not respond well to conventional ther-
apy [75]. There are no publications linking metaplastic
breast cancer to soy diets or cultures that consume high
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been associated with metaplasia in other tissues. Squa-
mous metaplasia and hyperplasia has been observed in the
uterus of female rats fed genistein for 52 weeks [76,77].
Moreover, administration of genistein to a murine mam-
mary or murine melanoma cell line induced the cells to
acquire a spindle-shaped morphology [65]. As our under-
standing of metaplastic breast cancer improves, it will be
interesting to see if dietary soy can influence the incidence
of this breast cancer subtype.Conclusions
In conclusion, our study indicates that extremely high
levels of dietary soy can promote mammary tumor de-
velopment induced by overexpression of the tyrosine
kinase receptor, IGF-IR. This increased susceptibility to
transformation in the soy-fed mice appears to be associ-
ated with increased expression of Areg. Future studies
should examine the impact of different levels of dietary
soy on mammary tumor development and whether soy
regulates Areg expression. Determining whether lower
levels of dietary soy can inhibit mammary tumorigenesis
and whether Areg expression has potential as a biomarker
for predicting breast cancer risk may have important im-
plications for prevention and treatment of this disease.Additional files
Additional file 1: Table S1. Nutritional information for the different
diets utilized in this study. The casein diet represents the diet where the
sole source of dietary protein was derived from casein while the soy diet
represents the diet where the sole source of dietary protein was derived
from isolated soy protein. The casein + DOXC and soy + DOXC represent
the casein and soy diets containing 100 mg/kg of doxycycline.
Additional file 2: Figure S1. Mammary tumor onset and IGF-IR expression
in response to different concentrations of doxycycline. Panel A shows the
average mammary tumor onset as measured in days post IGF-IR transgene
induction using concentration of doxycycline ranging from 100 mg/kg to
2000 mg/kg. Western blot analysis (B) and quantification of the blot (C) for
IGF-IR protein induced by 2 g/kg DOXC or 100 mg/kg DOXC in MTB-IGFIR
mice treated with DOXC for 14 days. The 2 g/kg DOXC induced significantly
more IGF-IR protein than the 100 mg/kg DOXC, p < 0.05 and indicated by
the asterisk. β-actin served as a loading control.
Additional file 3: Figure S2. Immunohistochemistry for IGF-IR in a
mammary gland from casein-fed mice treated with DOXC that did not
develop a mammary tumor (A) or a mouse that did not receive DOXC
(B). IGF-IR protein was highly expressed (brown stain) in mammary
epithelial cells of the DOXC-treated, casein-fed mice that did not develop
tumors indicating that the IGF-IR transgene was still highly expressed in
mammary tissue of these tumor-free, casein-fed mice. Scale bars, 100 μM.
Additional file 4: Figure S3. A box plot showing the level of staining
for cytokeratin 5, cytokeratin 14 and p63 in mammary tumors from soy- and
casein-fed mice. Tumors staining for each of the proteins in less than 1% of
the tumor cells are indicated by light green boxes while tumors containing
1-5% positive cells are indicated by dark green boxes, 6-10% positive cells
indicated by light red boxes and >10% positive cells indicated by dark red
boxes.
Additional file 5: Figure S4. Immunohistochemistry for IGF-IR in a
representative lung section showing that the lung metastases retain highlevels of IGF-IR protein (A) that can be used to detect very small lung
metastases (A,B). Scale bar in A is 100 μM while the scale bar in B is 33 μM.
Additional file 6: Figure S5. H&E stained section (A) and IGF-IR
immunohistochemistry (B) of a lung from a casein-fed mouse that
had extensive lung metastases in all lung lobes. H&E stained section
of the primary mammary tumor that produced the extensive lung
metastases is shown in (C). The histology of this tumor differed
from most of the other tumors in that the mammary tumor cells
still maintained glandular structures that were separated by stroma.
Scale bars in A, B are 800 μM while the scale bar in C is 100 μM.
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